Versant Venture Capital VI, L.P.'s Form 4 filing
LENZ Therapeutics, Inc. (LENZ) · filed Aug 26, 2025
- Accession no.
- 0000950170-25-111529
- Filed
- Aug 26, 2025, 7:59 PM ET
- Trade date
- Aug 22-26, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 12 non-derivative transactions and 0 derivative transactions. Open-market sales total $7.42M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Versant Venture Capital VI, L.P.CIK 0001687880 | 10% Owner |
| Versant Venture Capital VII, L.P.CIK 0001750266 | 10% Owner |
| Versant Ventures VI GP-GP, LLCCIK 0001777652 | 10% Owner |
| Versant Ventures VI GP, L.P.CIK 0001777654 | 10% Owner |
| Versant Ventures VII GP, L.P.CIK 0001777655 | 10% Owner |
| Versant Ventures VII GP-GP, LLCCIK 0001777656 | 10% Owner |
| Versant Vantage II, L.P.CIK 0001832235 | 10% Owner |
| Versant Vantage II GP-GP, LLCCIK 0001839789 | 10% Owner |
| Versant Vantage II GP, L.P.CIK 0001839790 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 22, 2025 | Common Stock | SSaleDisposed | −20,493 | $40.03 | −$820,328.64 | 1,379,727 | Direct | |
| Aug 22, 2025 | Common Stock | SSaleDisposed | −10,076 | $40.03 | −$403,339.26 | 952,802 | Indirect | |
| Aug 22, 2025 | Common Stock | SSaleDisposed | −5,668 | $40.59 | −$230,063.55 | 1,374,059 | Direct | |
| Aug 22, 2025 | Common Stock | SSaleDisposed | −2,809 | $40.59 | −$114,017.03 | 949,993 | Indirect | |
| Aug 25, 2025 | Common Stock | SSaleDisposed | −50,270 | $39.53 | −$1,986,946.89 | 1,323,789 | Direct | |
| Aug 25, 2025 | Common Stock | SSaleDisposed | −24,760 | $39.53 | −$978,651.38 | 925,233 | Indirect | |
| Aug 25, 2025 | Common Stock | SSaleDisposed | −2,149 | $39.92 | −$85,790.66 | 1,321,640 | Direct | |
| Aug 25, 2025 | Common Stock | SSaleDisposed | −1,058 | $39.92 | −$42,236.63 | 924,175 | Indirect | |
| Aug 26, 2025 | Common Stock | SSaleDisposed | −43,978 | $38.97 | −$1,714,016.16 | 1,277,662 | Direct | |
| Aug 26, 2025 | Common Stock | SSaleDisposed | −21,661 | $38.97 | −$844,224.48 | 902,514 | Indirect | |
| Aug 26, 2025 | Common Stock | SSaleDisposed | −3,465 | $39.50 | −$136,875.12 | 1,274,197 | Direct | |
| Aug 26, 2025 | Common Stock | SSaleDisposed | −1,707 | $39.50 | −$67,430.26 | 900,807 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.